Nutra Pharma Corp., a biotechnology holding company that owns rights to intellectual property related to the development of drugs for HIV and Multiple Sclerosis, has today announced that it has been selected by Platinum Television Group to be featured in a segment entitled, "Bringing Bio-Technologies to Market". The airing will be confirmed at a later date, but will likely be in the second quarter of 2005. The initial production will be shown on the highly acclaimed television series, "Business and Beyond" and featured on CNBC. Repeat airings, according to the Platinum Television Group, will occur 100 times in 25 leading markets across the United States. The show will focus on the research being conducted in diseases that lack therapeutic options, specifically Adrenomyeloneuropathy (AMN) and Multiple Sclerosis (MS).
"We are excited at the opportunity to present the Company's business model on Business and Beyond," stated Rik Deitsch, Nutra Pharma's Chairman and Chief Executive Officer. "The goal of the segment is to provide the audience with a basic understanding of the business side of biotechnology. Having strong patents and solid science is only the beginning. Many great ideas never make it to the marketplace. Nutra Pharma endeavors to act as an incubator in providing a business base to our biotechnology holdings," he concluded.
In the interview, Mr. Deitsch discusses Nutra Pharma's focus as an incubator of under-valued biotechnology holdings and the Company's short-term outlook. He also focuses on the research being conducted in diseases that lack therapeutic options, specifically Adrenomyeloneuropathy (AMN) and Multiple Sclerosis (MS).
This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). The interview with the Wall Street Reporter should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.